CytomX/CTMX

$2.65

0%
-
1D1W1MYTD1YMAX

About CytomX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies (TCBs), and immune modulators such as cytokines and checkpoint inhibitors (CPIs). Its clinical pipeline also includes cancer immunotherapeutic candidates. Its product candidates include CX-2029, CX-904, CX-2051, CX-801 and BMS-986288. Its CX-2029 is a Probody ADC targeting CD71 for the treatment of patients with squamous non-small cell lung carcinoma (sqNSCLC) and esophageal cancers.

Ticker

CTMX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sean Mccarthy

Employees

116

Headquarters

South san francisco, United States
Website
cytomx.com

CytomX Metrics

BasicAdvanced
$177.52M
Market cap
-
P/E ratio
-$0.45
EPS
1.02
Beta
-
Dividend rate

What the Analysts think about CytomX

Analyst Ratings

Majority rating from 7 analysts.
Hold

Price Targets

Average projection from 5 analysts.
3.02% upside
High $3.50
Low $1.60
$2.65
Current price
$2.73
Average price target

CytomX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
11.02% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$26.3M
6.48%
Net income
$2.9M
-390%
Profit margin
11.02%
-372.77%

CytomX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 121.18%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.43
-$0.05
-$0.02
$0.04
-
Expected
-$0.24
-$0.11
-$0.21
-$0.19
-$0.03
Surprise
82.55%
-52.72%
-90.24%
-121.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell CytomX stock

Buy or sell CytomX stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing